Pacific Edge (ASX: PEB) is an Australian-listed company in the Healthcare sector with a market capitalisation of $293.0M and the 573rd-largest security on the ASX by market capitalisation. The PEB share price is $0.25, up 2.04% today and up 206.25% over the past 12 months. Shares have traded between $0.08 and $0.26 over the past 52 weeks. In its most recent reported period (ending 31 Mar 2026), Pacific Edge reported revenue of $5.6M and a net loss of $16.8M.
About Pacific Edge Limited
Pacific Edge Limited, a cancer diagnostics firm headquartered in Dunedin, New Zealand, and established in 2001, is dedicated to the research, development, and commercialization of advanced diagnostic and prognostic tools. These innovations are designed for the early identification and ongoing management of various cancers, with the company's activities spanning New Zealand, the United States, Australia, and Singapore. Its operations are divided into distinct Commercial and Research segments. Central to its product offerings is Cxbladder, a suite of genomic urine tests specifically tailored for the detection and clinical management of bladder cancer. The company is actively expanding this portfolio with several new developments: Cxbladder Resolve, which aims to identify patients likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, designed to flag individuals with haematuria who have a low probability of bladder cancer; Cxbladder Detect, enabling the non-invasive discovery of bladder and other urinary tract cancers; and Cxbladder Monitor, a tool for urologists to track bladder cancer recurrence in patients. In addition to its focus on bladder cancer, Pacific Edge is also progressing with Cxcolorectal, a prognostic gene signature intended for patients diagnosed with stage II or stage III colorectal cancers. Furthermore, the company's development pipeline includes products targeting diagnostics for bladder, gastric, colorectal, and endometrial cancers, as well as melanoma.
